News
It also helps that Seqirus is moving toward what it deems a “differentiated and high value” flu vaccine portfolio, driven by its latest quadrivalent flu shots—Fluad Quad, Flucelvax Quad and ...
Seqirus advised of “some adverse events” for Flucelvax Quad recorded in children and adults during clinical trials. “But they were generally mild to moderate in nature,” the company said.
SUMMIT, N.J., July 11, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that it has begun to ship its portfolio of ...
CSL Seqirus, a business of CSL (ASX: CSL), today announced that it has commenced shipping its differentiated portfolio of influenza vaccines. This year, the company's influenza vaccines are being ...
Hosted on MSN4mon
Vaccine maker's revenue plunges as immunisation rates fall - MSNRevenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant fall in immunisation rates, particularly in the US. CSL Seqirus brought in ...
A new flu shot is FDA approved for kids as young as six months old. You might not know that the shot is being made in Wake County. Today's announcement from Seqirus about its flu vaccine's FDA ...
CSL’s new generation of influenza vaccine — dubbed its ‘super jab’ — has won regulatory approval for use on toddlers ahead of the winter cold season and amid record demand for its flu shots.
Seqirus advised of “some adverse events” for Flucelvax Quad recorded in children and adults during clinical trials. “But they were generally mild to moderate in nature,” the company said.
Seqirus advised of “some adverse events” for Flucelvax Quad recorded in children and adults during clinical trials. “But they were generally mild to moderate in nature,” the company said.
CSL’s new generation of influenza vaccine — dubbed its ‘super jab’ — has won regulatory approval for use on toddlers ahead of the winter cold season and amid record demand for its flu shots.
CSL’s new generation of influenza vaccine — dubbed its ‘super jab’ — has won regulatory approval for use on toddlers ahead of the winter cold season and amid record demand for its flu shots.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results